Navigation Links
Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Date:3/14/2008

ROCKVILLE, Md., March 14 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) today announced financial results for the fourth quarter and year ended December 31, 2007. Novavax reported a net loss of $9.2 million ($0.15 loss per share) for the fourth quarter of 2007 compared to a net loss of $6.1 million ($0.10 loss per share) in the fourth quarter of 2006. For the year ended December 31, 2007, the Company reported a net loss of $34.8 million ($0.57 loss per share) compared to a net loss of $23.1 million ($0.39 loss per share) for the year ended December 31, 2006. Novavax ended 2007 with $46.5 million in cash and investments compared to $73.6 million as of December 31, 2006. The total cash burn rate for the fourth quarter of 2007 was $6.8 million.

Among key achievements since January 1, 2007, Novavax has:

-- Advanced its H5N1 pandemic influenza vaccine to Phase I/IIa clinical

studies in humans. An interim analysis in December 2007 was positive,

indicating that this vaccine demonstrated immunogenicity at 15 mcg. and

45 mcg. dose levels and that the vaccine is well tolerated from a

safety perspective. Beginning March 2008, additional patients will be

enrolled in a dose-ranging study to determine the optimal dose.

Novavax expects that preliminary immunogenicity results from this study

should be available by early in the third quarter of 2008.

-- Advanced its seasonal influenza program into pre-clinical studies with

a target of commencing human trials in Phase I/IIa in late second

quarter or early third quarter of 2008. The initial results from our

pandemic influenza study bode well for our seasonal program, because


'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 In response to urgent requests from the ... Sierra Leone , Direct Relief delivered two 10-bed ... the treatment of local health workers who contract Ebola while ... Ebola care center was constructed for foreign health care workers ... available for local Sierra Leonean health workers. With ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Aug. 3 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Tuesday, August 10, 2010 at 8:00 a.m. Eastern Time ( 5:00 ... Interested parties may access ... , , ...
... , CLEVELAND , Aug. 3 Researchers ... Washington University School of Medicine in St. Louis, ... use of advanced treatments for cancer patients, will soon become ... system from ViewRay™, Inc. The ViewRay system is designed to ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference 2Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System 2Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... of $39.2 MillionCARLSBAD, Calif., April 30 Genoptix, Inc. ... provider, today reported revenues of $39.2 million for the ... benefit from changes in accounting estimates relating to prior ... over revenues of $22.3 million for the comparable period ...
... risks, agency says, , , THURSDAY, April 30 (HealthDay News) ... injections such as Botox to treat muscle spasms have ... products will now be required to carry boxed warnings, ... Food and Drug Administration announced Thursday. , Most cases ...
... HealthSouth Corporation (NYSE: HLS ) today announced ... Stock Conference on May 12-14, 2009, at the Four Seasons ... and Executive Vice President and Chief Financial Officer John Workman ... ET (7:55 a.m. CT). The presentation will be webcast live ...
... The Missouri House today amended HB21 to allocate at ... grants for maternity homes and pregnancy resource centers in the ... Missouri Senate. , , Americans United for Life ... centers are essential to helping pregnant women in need. ...
... Prospero Group (PRPG) invested into the Private ... split. Prospero Group a leading company in the field ... the new ACTRx Malaria and Dengue fever treatment. Fincor ... Prospero Group enlarges its technology portfolio with ...
... can have significant physical and psychological repercussions that impact ... it can affect their ability to remain employed. Compared ... disabilities, arthritis appears to have a more profound effect ... found that about half of those with severe forms ...
Cached Medicine News:Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 2Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 3Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 4Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 5Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 6Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 7Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 8Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 9Health News:FDA Mandates New Warnings for Botox 2Health News:FDA Mandates New Warnings for Botox 3Health News:Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment 2Health News:Women with arthritis more likely than men to stop working 2Health News:Women with arthritis more likely than men to stop working 3
... Prostate specific antigen (PSA) is a serine ... within the epithelial cells of the acini and ... serum is 0.1-2.6 ng/mL. Reports have suggested that ... is the must useful tumor markers in diagnosis ...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
A complete workstation for haemostasis , A compact and convenient analyser , A comprehensive system , An exellent reliability: the STAGO patented detection mode...
... Lancets are designed with Shallow Point Comfort ... gauge needle with its shallow-angled edges act ... penetration without tearing the skin. The unique ... to grip, even for patients with arthritis ...
Medicine Products: